uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Topoisomerase II-α Expression in Different Cell Cycle Phases in Fresh Human Breast Carcinomas
Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Oncology.
Show others and affiliations
2002 In: Modern Pathology, ISSN 0893-3952, Vol. 15, no 5, 486-491 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2002. Vol. 15, no 5, 486-491 p.
URN: urn:nbn:se:uu:diva-95410OAI: oai:DiVA.org:uu-95410DiVA: diva2:169604
Available from: 2007-02-02 Created: 2007-02-02Bibliographically approved
In thesis
1. Chemosensitivity in Breast Cancer
Open this publication in new window or tab >>Chemosensitivity in Breast Cancer
2007 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Breast cancer mortality in Sweden is now in decline, thanks to early detection and the wide use of adjuvant endocrine therapy and chemotherapy.

While hormone receptor status is predictive of response to endocrine treatment, there is no clinically useful predictive marker of a patient’s response to chemotherapy. Consequently, patients receive chemotherapy with considerable toxicity but minimal benefit. The aim of this thesis was to investigate a number of methods with the potential to predict response to chemotherapy and thus enhance treatment efficacy in breast cancer patients.

We found that topo IIα, the key target enzyme of topo II inhibitors, is significantly expressed in nonproliferating breast cancer cells. This finding may explain why topo II inhibitors are effective in patients with slow growing tumors and a low proliferation rate.

Topo IIα gene amplification was suggestive of increased response to anthracyclines in advanced breast cancer, whereas the oncogene HER2 had no predictive value by itself. These findings are in accordance with current knowledge.

Cyclin A, a marker of cell proliferation, showed good prognostic value but did not predict response to chemotherapy in advanced breast cancer.

In vitro chemosensitivity testing with FMCA predicted tumor response in patients with advanced breast cancer with a sensitivity of 89% and a specificity of 53%. Our results are consistent with the results from similar assays, which predict drug resistance with good accuracy while clinical drug sensitivity is less reliably predicted. The use of FMCA and similar assays is not yet recommended outside clinical trials; their main utility is in preclinical testing of new anti-cancer drugs, including targeted therapies.

The combination of epirubicin, capecitabine, and cisplatin (EXC) demonstrated high clinical response rate (74%) and pathological complete response rate (22%) in locally advanced breast cancer, but with cumbersome toxicity. The fluoropyrimidine biomarkers TS, TP, and DPD did not predict response to the EXC regimen.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2007. 83 p.
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 221
Oncology, breast cancer, chemotherapy, anthracycline, predictive, topoisomerase, TOP2A, HER2, cyclin A, in vitro, Onkologi
urn:nbn:se:uu:diva-7459 (URN)978-91-554-6787-6 (ISBN)
Public defence
2007-02-23, Wilandersalen, M-huset, Universitetssjukhuset, Örebro, 13:15
Available from: 2007-02-02 Created: 2007-02-02Bibliographically approved

Open Access in DiVA

No full text

By organisation

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 156 hits
ReferencesLink to record
Permanent link

Direct link